Hepatitis C Genotypes
|
|
- Sydney Shepherd
- 6 years ago
- Views:
Transcription
1 9/2/21 OBJECTIVES Project ECHO HCV Collaborative HCV in 21: New Therapies and New Opportunities Paulina Deming, PharmD Assistant Director Hepatitis C Programs, ECHO Institute Associate Professor College of Pharmacy University of New Mexico Health Sciences Center Albuquerque, NM August 15, 21 Presentation prepared by: Date prepared: For pharmacists: 1. Describe the clinical and economic burden associated with hepatitis C virus (HCV) infection 2. Describe new therapeutic options for the treatment of chronic HCV 3. Use national algorithms and guidelines to guide treatment strategies for patients with HCV infection 4. Discuss challenges to HCV treatment in New Mexico For technicians: 1. Identify risk factors for chronic HCV infections 2. Recognize new HCV therapies 3. Describe health systems challenges which can affect outcomes of HCV therapy 4. Identify challenges to HCV treatment Hepatitis C is a Global Health Problem Estimated 1 million persons with HCV infection worldwide Hepatitis C Genotypes 6 major genotypes (1 6), most with subtypes Genotype 1 GT 1b different than GT 1a GT 2 easier to treat than GT 3 Prevalence of infection > 1% 2.5%-1% 1%-2.5% NA GT 3 associated with higher mortality, steatohepatitis World Health Organization 28 ( Alter MJ et al. N Engl J Med 1999; 341: Risk Factors for HCV Infection Hepatitis C: Progression of Disease Persons born between Normal Liver Time 2 25 years 25 3 years Received blood transfusion or organ donation prior to 1992 Current or former injection drug users Chronic hemodialysis patients Any known blood exposure to HCV positive blood Persons with HIV Children born to HCV infected mother HCV Infection Chronic Hepatitis Cirrhosis HCC ESLD Death 1
2 9/2/21 HCV is Not Just a Liver Disease Common Symptoms of HCV in Absence of Cirrhosis Fatigue Impaired cognitive function (brain fog) Migratory arthralgia or myalgia Depression Extrahepatic Manifestations of Chronic HCV Renal Disease Lymphomas Neuropathy Dermatologic Manifestations Diabetes Neurological Impairments Changes in HCV Therapy Goals of HCV Therapy Differences in Therapy Cure Defined as sustained virologic response (SVR) Improvements in liver function Improvements in fibrosis, reversal of cirrhosis? Improvements in extrahepatic manifestations of HCV Interferon Based Injectable Long duration of treatment High side effect profile Multiple laboratory abnormalities Low cure rates Direct Acting Antivirals Oral Short durations Minimal side effects Minimal laboratory abnormalities High cure rates The Evolution of Highly Effective Treatment HCV Direct Acting Antivirals (DAAs) 1 8 Standard IFN PegIFN BOC and TPV SOF SMV LDV/ SOF PrOD >9 >9 2 DCV+ EBR/ SOF GZR >9 >9 SOF/ VEL >9 21 SOF/ VEL/ GLE/ VOX PIB >9 >9 Target NS3/4A: Protease Inhibitors ( previr) Boceprevir Telaprevir Simeprevir Paritaprevir Grazoprevir Glecaprevir Voxilaprevir NS5A: Replication Complex Inhibitors ( asvir) Ledipasvir Ombitasvir Daclatasvir Elbasvir Velpatavir Pibrentasvir NS5B: Polymerase Inhibitors ( buvir) Nucleotide: Sofosbuvir Non nucleoside: Dasabuvir IFN 6 mos IFN mos IFN/ 6 mos IFN/ mos PegIFN mos PegIFN/ / BOC or TPV 6- mos PegIFN/ PegIFN/ LDV/ / / SOF SMV SOF PrOD SOF + DCV EBR/ GZR - SOF/ SOF/ GLE/ VEL VEL/ PIB VOX 8-2
3 9/2/21 Side Effect Profile of DAAs Laboratory Abnormalities Overall very well tolerated Most commonly reported side effects: Headache Fatigue Nausea Diarrhea (reported with voxilaprevir) Overall not common Most common laboratory abnormalities: ALT elevations Concomitant use of ethinyl estradiol with PrOD or glecaprevir/pibrentasvir Elbasvir/grazoprevir Bilirubin elevations Many DAAs inhibit bilirubin transporters Anemia with concomitant use of ribavirin Ribavirin causes hemolytic anemia Main Drug Interaction Concerns for DAAs Case Study: Managing Interactions New DAAs overall have low potential for causing drug drug interactions Amiodarone with sofosbuvir and other DAA: Serious symptomatic bradycardia Potential for other drugs to lower DAA concentrations: Strong CYP3A inducers: carbamazepine, oxcarbazepine, phenobarbital, phenytoin Strong intestinal P glycoprotein inducers: rifabutin, rifampin, rifapentine St. John s wort Statins: Interactions vary by DAA and statin Acid suppressive therapy: Ledipasvir and velpatasvir solubility decreases with increases in ph Requires acidity for absorption 48 yo female admitted to hospital with orders including PPI drip Patient s home medications include ledipasvir/sofosbuvir Use of HCV DAAs in Renal Insufficiency and Cirrhosis Ledipasvir/ sofosbuvir Elbasvir/gra zoprevir Sofosbuvir/ velpatasvir Sofosbuvir/ velpatasvir/ voxilaprevir Glecaprevir/ pibrentasvir Use in renal impairment or endstage renal disease? > 3 ml/min Safe to use in all levels of renal impairment including dialysis > 3 ml/min > 3 ml/min Safe to use in all levels of renal impairment including dialysis druginteractions.org Also available as an app: hepichart Use in cirrhosis? Childs Class A, B or C Child Class A Childs Class A, B or C Child Class A Child Class A 3
4 9/2/21 Ledipavir/Sofosbuvir ION Phase 3 Program (ION 1, ION 2, ION 3) Efficacy Summary Harvoni [package insert]. Foster City, CA: Gilead Sciences, Inc.; 2. Combination of NS5B polymerase inhibitor (Sofosbuvir); NS5A inhibitor (ledipasvir) Administration One tablet once daily with food or without food Requires acidic environment for absorption Indicated for GT 1 and 4 SVR (%) LDV/SOF LDV/SOF / / 21 2/ 21 8 Weeks Weeks Weeks 24 Weeks Weeks 24 Weeks ION 1 GT 1 treatment naïve including cirrhotics ION 3 GT 1 treatment naïve non cirrhotic ION 2 GT 1 treatment experienced including cirrhotics and PI failures Afdhal N, et al. N Engl J Med 214; 214 Apr [Epub ahead of print] Kowdley K, et al. N Engl J Med 214; 214 Apr 11 [Epub ahead of print] Afdhal N, et al. N Engl J Med 214; 214 Apr [Epub ahead of print] 215/ 21 9% (1886/1952) overall SVR rate Error bars represent 95% confidence intervals. 22/ / 2 26/ 2 / 19 1/ / 19 11/ 111 Elbasvir/ Grazoprevir (EBR/GZR) Laboratory Abnormalities and Adverse Effects Fixed dose combination tablet 5 mg elbasvir (NS5A replication complex inhibitor) 1 mg grazoprevir (NS3/4A protease inhibitor) Dosing: 1 tablet per day with or without food Approved Feb. 2 Indicated for HCV genotypes 1 and 4 Patients with GT 1a require pre treatment resistance testing If present, must add ribavirin and extend treatment duration to weeks Increased risk of ALT elevations 5x ULN in 1% of patients 2% in women, Asian race, or patients aged 65 years or older Occurred at treatment week 8 or later Mostly asymptomatic Resolved with ongoing or completed therapy Monitor LFTs every 4 weeks or as clinically indicated Adverse effects: Fatigue, headache, and nausea Elbasvir Grazoprevir in Treatment Naïve HCV GT 1, 4 or 6 C EDGE TN: Results C EDGE TN: SVR Results by Genotype 299/3 144/15 9/131 18/18 8/1 Sofosbuvir/Velpatasvir Fixed dose combination of sofosbuvir (NS5B inhibitor) and velpatasvir (NS5A inhibitor) Approved June 28, 2 for chronic HCV genotypes 1, 2, 3, 4, 5, or 6 Treatment naïve Treatment experienced (Peg IFN/ with or without PI) Primary efficacy analysis included all patients who received 1 dose of drug. Epclusa [package insert]. Foster City, CA: Gilead Sciences, Inc.; 2. Source: Zeuzem S, et al. Ann Intern Med. 215;3:1-13. Slide courtesy of HCV Online; H. Nina Kim MD, MSc and David Spach MD 4
5 9/2/21 ASTRAL-1: SOF/VEL STR for Weeks in GT 1, 2, 4, 5, 6 HCV-Infected Patients SVR by Cirrhosis Status or Treatment History Sofosbuvir/Velpatasvir/Voxilaprevir SVR (%) / /51 /1 418/423 Total Non-Cirrhotic Cirrhotic Treatment- Naïve 2/21 Treatment- Experienced Combination of NS5B polymerase inhibitor (Sofosbuvir); NS5A inhibitor (Velapatasvir); NS3/4A protease inhibitor (Voxilaprevir) Administration One tablet once daily with food Approved July 18, 21 Vosevi [package insert]. Foster City, CA: Gilead Sciences, Inc.; 21. Error bars represent 95% confidence intervals. Feld, AASLD, 215, LB-2. Feld JJ, et al. N Engl J Med DOI: 1.156/NEJMoa Indications: DAA Treatment Experienced Patients Patients with genotype 1, 2, 3, 4, 5, or 6 who were previously treated with an NS5A inhibitor Patients with genotype 1a or 3 infection previously treated without an NS5A inhibitor No advantage of using sofosbuvir/velpatasvir/voxilaprevir over sofosbuvir/velpatasvir for retreatment of patients with GT 1b, 2, 4, 5, or 6 POLARIS 1: SOF/VEL/VOX for Weeks in NS5A Inhibitor Experienced HCV GT 1 6 SVR Results Overall and by Cirrhosis Status SVR, % relapses 1 on treatment failure** 2 withdrew consent 1 LTFU 253/263 1 withdrew consent 1 LTFU Overall* No Cirrhosis Cirrhosis 93 14/ /1 6 relapses 1 on treatment failure** 1 withdrew consent * p <.1 for superiority compared with prespecified 85% performance goal for SOF/VEL/VOX ** Exposure was consistent with non adherence Bourliere M, AASLD 2, Oral 194 POLARIS 1: SOF/VEL/VOX for Weeks in NS5A Inhibitor Experienced HCV GT 1 6 SVR by Genotype and Cirrhosis Status SVR, % * No Cirrhosis Overall GT 1 GT 1a GT 1b GT 2 GT 3 GT 4/5/6 *1/1 patient with GT unknown achieved SVR; 4/4 patients with GT 1 other (cirrhosis, n=2; no cirrhosis, n=2) achieved SVR; Includes only GT 4 patients Cirrhosis SVR, % POLARIS-4: SOF/VEL/VOX or SOF/VEL for Weeks in Non-NS5A Inhibitor DAA- Experienced HCV GT SOF/VEL/VOX Weeks Overall SVR 9% No Cirrhosis SVR by Genotype and Cirrhosis Status GT 1a GT 1b GT 2 GT 3 GT Cirrhosis SOF/VEL Weeks Overall SVR 9% GT 1a GT 1b GT 2 GT 3 GT Data on file, Gilead Sciences 29 Data on file, Gilead Sciences 3 5
6 9/2/21 Adverse Reactions and Laboratory Abnormalities Glecaprevir/Pibrentasvir Adverse reactions: Headache Fatigue Diarrhea Nausea Laboratory abnormalities: increases in total bilirubin Voxilaprevir can inhibit bilirubin transporters Combination of Glecaprevir an NS3/4A protease inhibitor Pibrentasvir an NS5A inhibitor Dosage and administration: 3 tablets once daily with food Approved Aug. 3, 21 Indications and Duration of Therapy Glecaprevir Pibrentasvir for 8 or weeks in Non Cirrhotic GT 1 ENDURANCE 1: Baseline Characteristics HCV Genotype Prior Treatment Experience Without Cirrhosis With Compensated Cirrhosis 1,2,3,4,5,6 Naïve 8 weeks weeks 1,2,4,5,6 Pegylated interferon, ribavirin and/or sofosbuvir 8 weeks weeks 3 Pegylated interferon, ribavirin and/or sofosbuvir weeks weeks 1 NS3/4A (NS5A naïve) weeks weeks NS5A (NS3/4A naïve) weeks weeks Patients (%) with SVR ITT-PS GLE-PIB x 8 Weeks GLE-PIB x Weeks 332/ / / /332 ITT-PS-PP ITT-PS population: ITT excluding patients with HIV coinfection or treatment experience with sofosbuvir ITT-PS-per protocol (PP) population: ITT-PS excluding patients with premature discontinuation of study drug, virologic failure before Week 8, and missing SVR data Source: Zeuzem S, et al. AASLD 2.Abstract 253. Patients with SVR (%) Glecaprevir Pibrentasvir in Treatment Naïve Non Cirrhotic GT 3 ENDURANCE 3 Study: Results 1 ION-3: SVR by Treatment Duration and Regimen (ITT Analysis) /233 GLE-PIB SOF + DCV GLE-PIB -Week Regimens GLE-PIB = glecaprevir-pibrentasvir; SOF = sofosbuvir; DCV = daclatasvir ITT = Intent-to-treat Source: Foster G, et al. EASL 21. Abstract GS-. 111/ /15 8-Week Regimen Patients with SVR (%) Glecaprevir Pibrentasvir in Genotype 1 6 with Renal Disease EXPEDITION 4: Results Source: Gane E, et. al, AASLD 2. Abstract 935. SVR by Type of Analysis discontinuation 1 lost to follow-up /14 / ITT mitt ITT, intent-to-treat analysis; mitt, modified intent-to-treat analysis 6
7 9/2/21 Adverse Reactions and Laboratory Abnormalities Adverse reactions reported: Headache, fatigue, nausea, diarrhea Rates similar to placebo Laboratory abnormalities: Serum bilirubin abnormalities in approximately 3% of patients Glecaprevir/pibrentasvir can affect bilirubin transporters Joint guidelines of the American Association for the Study of Liver Diseases (AASLD) and Infectious Diseases Society of America (IDSA) Updated frequently check online for most current version of guidelines Available at: New Mexico has the highest prevalence of HCV in the US Milliman 213: Health Care Reform and Hepatitis C: Convergence of Risk and Opportunity (analysis of NHANES, MarketScan 21, Medicare 5% Sample, and Medicaid Contributor data. Does not include prison population). HCV in New Mexico.4% 1.3% Slide courtesy Dr. David Scrase Centennial Treatment Criteria Expanded Effective Sept 15, 21 All members over age 1, all HCV genotypes, with F level or greater of fibrosis Case Study: Systems Challenges to Effective Therapy Patient on HCV therapy At 4 5 weeks of therapy, questions regarding use and dosing of ribavirin were identified and pharmacist did not authorize refill of therapy to complete HCV course until these issues were clarified
8 9/2/21 Conclusions Remaining Challenges in HCV Therapy Chronic HCV infections pose a high healthcare burden DAA therapies are highly effective with SVR rates >9% New therapies available for patients with all genotypes, renal insufficiency, and prior DAA failure Regimens are well tolerated, have limited drug interactions, and few laboratory abnormalities Need for increased screening to identify patients and link to treatment HCV treatment in patients with decompensated cirrhosis Screening and identifying patients with chronic HCV Treatment interruptions Concerns for HCV resistance Access to HCV therapy Resources Project ECHO HCV Collaborative AASLD/IDSA HCV Treatment Guidelines: Available at: HCV Drug Interactions (University of Liverpool): Available at: druginteractions.org Educational material, clinical calculators, HCV therapy summaries (University of Washington) Available at: End of Presentation Questions? 8
HCV in 2017: New Therapies and New Opportunities. Presentation prepared by: Date prepared: OBJECTIVES
Project ECHO HCV Collaborative HCV in 217: New Therapies and New Opportunities Paulina Deming, PharmD Assistant Director Hepatitis C Programs, ECHO Institute Associate Professor College of Pharmacy University
More information1/16/2019. Goals of HCV Therapy. Objectives. Treating Hepatitis C and HIV Co Infection. Cure Defined as sustained virologic response (SVR)
HCV ECHO WESTERN STATES HCV ECHO WESTERN STATES Treating Hepatitis C and HIV Co Infection Paulina Deming, Pharm D Associate Professor, College of Pharmacy Assistant Director, Viral Hepatitis Programs,
More informationHCV Screening, Management, and Treatment Guidelines
HCV ECHO WESTERN STATES HCV Screening, Management, and Treatment Guidelines Paulina Deming, PharmD, PhC Associate Professor of Pharmacy-College of Pharmacy Project ECHO University of New Mexico Health
More informationHCV Screening, Management and Guidelines
HCV ECHO WESTERN STATES HCV Screening, Management and Guidelines Paulina Deming, PharmD, PhC Associate Professor of Pharmacy-College of Pharmacy Project ECHO University of New Mexico Health Sciences Center
More information2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients
2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients Jens Rosenau, MD Associate Professor of Medicine Acting Director
More informationAnnual Hepatitis C Update
Annual Hepatitis C Update Target Audience: Pharmacists ACPE#: 0202-0000-18-064-L01-P Activity Type: Knowledge-based Target Audience: ACPE#: Activity Type: This activity is supported by an independent educational
More informationDescription of Antivirals for Hepatitis C. LCDR Dwayne David, PharmD, BCPS, NCPS Cherokee Nation Infectious Diseases
Description of Antivirals for Hepatitis C LCDR Dwayne David, PharmD, BCPS, NCPS Cherokee Nation Infectious Diseases Dwayne-David@cherokee.org Objectives Compare the different classes of direct-acting antiviral
More informationHEPATITIS C: UPDATE AND MANAGEMENT
HEPATITIS C: UPDATE AND MANAGEMENT José Franco, MD Professor of Medicine Associate Dean for Educational Improvement Associate Director, Kern Institute STAR Center Director José Franco, MD Disclosures I
More informationNew Antivirals for Hep C in Context of HIV: Vosevi and Mavyret
New Antivirals for Hep C in Context of HIV: Vosevi and Mavyret John Scott, MD, MSc, FIDSA November 16, 2017 This presentation is intended for educational use only and does not in any way constitute medical
More informationHepatitis C Update: What s New in 2017
Hepatitis C Update: What s New in 2017 Cody A. Chastain, MD Assistant Professor of Medicine Viral Hepatitis Program Division of Infectious Diseases Vanderbilt University Medical Center Cody.a.Chastain@Vanderbilt.edu
More informationSelecting HCV Treatment
Selecting HCV Treatment Caveats Focus on treatment selection for genotypes 1, 2, and 3. Majority of US population infected with GT 1, 2, or 3 GT 4 treatment closely reflects GT 1 treatment GT 5 and 6 are
More informationViva La Revolución: Options to Combat Hepatitis C
Viva La Revolución: Options to Combat Hepatitis C David L. Wyles, MD Professor of Medicine University of Colorado Chief, Division of Infectious Disease Denver Health Learning Objectives After attending
More informationOn Target for Hepatitis C Elimination: Direct Acting Antiviral Agents in 2018
On Target for Hepatitis C Elimination: Direct Acting Antiviral Agents in 2018 Trana Hussaini, PharmD Pharmacotherapy Specialist in Liver Transplantation, VGH Clinical Assistant Professor, Faculty of Pharmaceutical
More informationDirect-acting Antiviral (DAA) Regimens in Late-stage Development: Which Patients Should Wait? Fred Poordad, MD
Direct-acting Antiviral (DAA) Regimens in Late-stage Development: Which Patients Should Wait? Fred Poordad, MD The HCV Lifecycle: Multiple Targets Polymerase Inhibitors Protease Inhibitors NS5A Inhibitors
More informationHCV Treatment in 2016: Genotypes 1, 2, and 3. Cody A. Chastain, MD October 12, 2016
HCV Treatment in 2016: Genotypes 1, 2, and 3 Cody A. Chastain, MD October 12, 2016 Disclosures I have no financial disclosures. Caveats I will only discuss treatment of GT 1-3. Majority of US population
More informationCurrent HCV Treatment by Genotype
Current HCV Treatment by Genotype Ari Bunim, MD Assistant Professor Clinical Medicine Weill Cornell Medical College Clinical Director of Hepatology New York-Presbyterian/Queens Objectives To understand
More informationHepatitis C Resistance Associated Variants (RAVs)
Hepatitis C Resistance Associated Variants (RAVs) Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Nothing to disclose Disclosure
More informationNew York State HCV Provider Webinar Series. Side Effects of Therapy and Drug-Drug Interactions
New York State HCV Provider Webinar Series Side Effects of Therapy and Drug-Drug Interactions Case Presentation Case 56 year-old lady with Genotype 1A Hepatitis C, Treatment-naive Noninvasive fibrosis
More informationPHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline
PHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline Preferred Regimen Based on Diagnosis: Mavyret (glecaprevir/pibrentasvir ) Non-Preferred: Daklinza (daclatasvir) Epclusa (sofosbuvir/velpatasvir)
More informationManagement of HCV in Prior Treatment Failure
Management of HCV in Prior Treatment Failure Arthur Y. Kim, MD Associate Professor of Medicine Harvard Medical School Boston, Massachusetts Learning Objectives After attending this presentation, learners
More informationSovaldi (sofosbuvir)
Market DC Sovaldi (sofosbuvir) Override(s) Prior Authorization Quantity Limit Approval Duration Based on Genotype, Treatment status, Cirrhosis status, or Ribavirin Eligibility status **IN, SC, WA Medicaid
More informationHarvoni (sofosbuvir/ledipasvir
Market DC Override(s) Prior Authorization Quantity Limit (sofosbuvir/ledipasvir) Approval Duration Based on Genotype, Treatment status, Baseline HCV RNA status, Cirrhosis status, Transplant status, or
More informationPHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline
Preferred Regimen Based on Diagnosis: Mavyret (glecaprevir/pibrentasvir) PHARMACY PRI AUTHIZATION Hepatitis C Clinical Guideline Non-Preferred: Daklinza (daclatasvir) Epclusa (sofosbuvir/velpatasvir) Harvoni
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Hepatitis C Second Generation Antivirals Page 1 of 32 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Hepatitis C Second Generation Antivirals Through
More informationNew York State HCV Provider Webinar Series. Side Effects of Therapy and Drug-Drug Interactions
New York State HCV Provider Webinar Series Side Effects of Therapy and Drug-Drug Interactions Case Presentation Case 56 year-old lady with Genotype 1A Hepatitis C, Treatment-naive Noninvasive fibrosis
More informationUpdate on Real-World Experience With HARVONI
Update on Real-World Experience With A RESOURCE FOR PAYERS This information is intended for payers only. The HCV-TARGET and TRIO studies were supported by Gilead Sciences, Inc. Real-world experience data
More informationEpclusa (Sofosbuvir/Velpatasvir) for HIV/HCV
Mountain West AIDS Education and Training Center Epclusa (Sofosbuvir/Velpatasvir) for HIV/HCV John Scott, MD, MSc Associate Professor University of Washington Jul 28, 2016 This presentation is intended
More informationDrug Class Prior Authorization Criteria Hepatitis C
Drug Class Prior Authorization Criteria Hepatitis C Line of Business: Medicaid P & T Approval Date: Interim Criteria Pending P&T Approval Effective Date: August 16, 2018 This drug class prior authorization
More informationOptimizing HCV Treatment Continuity and Outcomes
Optimizing HCV Treatment Continuity and Outcomes Empowering Pharmacists to Take Action Faculty Michelle T. Martin, PharmD, BCPS, BCACP Clinical Pharmacist University of Illinois Hospital and Health Sciences
More informationHCV therapy : Clinical case
HCV therapy : Clinical case PHC 2018 Paris January 14th, 2018 Tarik Asselah (MD, PhD) Professor of Medicine Hepatology, Chief INSERM UMR 1149, Hôpital Beaujon, Clichy, France. Disclosures Professor Asselah
More informationKristen M. Marks, MD Assistant Professor Weill Cornell Medical College New York, New York
Newly Approved Hepatitis C Virus Drugs: Approach to Initial Therapy Kristen M. Marks, MD Assistant Professor Weill Cornell Medical College New York, New York Learning Objectives After attending this presentation,
More information5/12/2016. Learning Objectives. Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients
5/12/216 Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients Alexander Monto, MD Professor of Clinical Medicine University of California San Francisco San Francisco,
More informationHepatitis C Update: Screening, Diagnosis, and Treatment
Mountain West AIDS Education and Training Center Hepatitis C Update: Screening, Diagnosis, and Treatment Brian R. Wood, MD (bwood2@uw.edu) Assistant Professor of Medicine, University of Washington Medical
More informationCurrent trends in CHC 1st genotype treatment
Current trends in CHC 1st genotype treatment Tarik Asselah MD, PhD Professor of Medicine Hepatology, Chief INSERM UMR 1149, Hôpital Beaujon, Clichy, France Disclosures Employee of Paris Public University
More informationNew York State HCV Provider Webinar Series. Side Effects of Therapy
New York State HCV Provider Webinar Series Side Effects of Therapy Objectives Understand the basics of HCV therapy Review the currently available regimens for treatment of HCV Appreciate side effects related
More informationCurrent HCV Treatment by Genotype Ira M. Jacobson, MD
Current HCV Treatment by Genotype Ira M. Jacobson, MD Director of Hepatology NYU School of Medicine Objectives To understand the prevalence of HCV and distribution of HCV genotypes Describe the HCV lifecycle
More informationTHE THERAPEUTIC REVOLUTION THAT TRANSFORMED CHRONIC HEPATITIS C TO A CURABLE DISEASE
THE THERAPEUTIC REVOLUTION THAT TRANSFORMED CHRONIC HEPATITIS C TO A CURABLE DISEASE MARIA SCHINA CONSULTANT PHYSICIAN INTERNAL MEDICINE AND HEPATOLOGY ATHENS EUROCLINIC 10 th INTERNATIONAL CONGRESS OF
More informationShorter Durations and Pan-genotypic Regimens The Final Frontier. Professor Greg Dore
Shorter Durations and Pan-genotypic Regimens The Final Frontier Professor Greg Dore Disclosures Funding and speaker fees from AbbVie, Bristol-Myers Squibb, Gilead Sciences and Merck Efficacy Evolution
More informationIFN-free for Genotype 1 HCV: the current landscape. Prof. Graham R Foster
IFN-free for Genotype 1 HCV: the current landscape Prof. Graham R Foster Wonderful new drugs are coming Poordad F, et al. New Engl J Med 2014; online DOI: 10.1056/NEJMoa1402869. 2 The New Drugs Two treatment
More informationSOFOSBUVIR/VELPATASVIR Generic Brand HICL GCN Exception/Other SOFOSBUVIR/ VELPATASVIR
Generic Brand HICL GCN Exception/Other SOFOSBUVIR/ VELPATASVIR EPCLUSA 43561 GUIDELINES FOR USE 1. Is the patient at least 18 years old? If yes, continue to #2. 2. Does the patient have a diagnosis of
More informationDirect Acting Antivirals for the Treatment of Hepatitis C Infection
Hepatitis C Core Curriculum, Module 2 Direct Acting Antivirals for the Treatment of Hepatitis C Infection Jason J. Schafer, PharmD, MPH, BCPS, AAHIVP Objectives Discuss the evolution of hepatitis C treatment
More informationUpdates in the Treatment of HCV
Updates in the Treatment of HCV Misty Miller, Pharm.D., BCPS, AAHIVP Associate Professor University of Oklahoma College of Pharmacy September 21 st, 2018 Overview HCV Review and Definitions HCV Genotypes
More informationHCV Resistance Clinical Aspects. Sanjay Bhagani Royal Free Hospital/UCL London
HCV Resistance Clinical Aspects Sanjay Bhagani Royal Free Hospital/UCL London DAAs in 2018, and beyond % patients % patients Changing characteristics of patients treated with DAA over time Prospective,
More informationUpdate on Real-World Experience With HARVONI
Update on Real-World Experience With A RESOURCE FOR PAYERS MAY 217 This information is intended for payers only. The HCV-TARGET study was supported by Gilead Sciences, Inc. Real-world experience data were
More informationHepatitis C Introduction and Overview
Hepatitis C Introduction and Overview Michael S. Saag, MD Professor of Medicine Associate Dean of Global Health Director, Center for AIDS Research University of Alabama at Birmingham Birmingham, Alabama
More informationLedipasvir-Sofosbuvir (Harvoni)
HEPATITIS WEB STUDY HEPATITIS C ONLINE Ledipasvir-Sofosbuvir (Harvoni) Robert G. Gish MD Professor, Consultant, Stanford University Medical Center Senior Medical Director, St Josephs Hospital and Medical
More informationCases: Initial Treatment of Hepatitis C
Cases: Initial Treatment of Hepatitis C Kristen Marks, MD Assistant Professor of Medicine Weill Cornell Medical College New York, New York Off-Label Warning I will discuss the following off-label use in
More informationHepatitis C Prior Authorization Policy
Hepatitis C Prior Authorization Policy Line of Business: Medi-Cal P&T Approval Date: November 15, 2017 Effective Date: January 1, 2018 This policy has been developed through review of medical literature,
More informationHepatitis C: The New World of Treatment
Hepatitis C: The New World of Treatment Aban 1395, NIOC Hospital Shahin Merat, M.D. Professor of Medicine Digestive Disease Research Institute Tehran University of Medical Sciences 1 Drugs NS5B polymerase
More informationDrug Class Prior Authorization Criteria Hepatitis C
Drug Class Prior Authorization Criteria Hepatitis C Line of Business: Medicaid P & T Approval Date: Interim (pending P&T approval) Effective Date: July 1, 2018 This policy has been developed through review
More informationHCV Treatment Options in 2017/2018: What s Here and What s Coming Soon
HCV Treatment Options in 2017/2018: What s Here and What s Coming Soon Supported by educational grants from AbbVie; Bristol-Myers Squibb; Gilead Sciences; Janssen Therapeutics; Merck & Co., Inc; and ViiV
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES
HARVARD PILGRIM HEALTH CARE Generic Brand HICL GCN Exception/Other DACLATASVIR DAKLINZA 41377 ELBASVIR/GRAZOPREVIR ZEPATIER 43030 GLECAPREVIR/PIBRENTASVIR MAVYRET 44453 OMBITASVIR/PARITAPREVIR/ RITONAVIR
More informationManagement of HIV/HCV Coinfection. Kristen M. Marks, MD Assistant Professor Weill Cornell Medical College New York, NY
Management of HIV/HCV Coinfection Kristen M. Marks, MD Assistant Professor Weill Cornell Medical College New York, NY Disclosure Dr. Marks has received grants and research support from Gilead Sciences
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Hepatitis C Second Generation Antivirals Page 1 of 30 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Hepatitis C Second Generation Antivirals Through
More informationUpdate on Hepatitis C. Francesco Negro Hôpitaux Universitaires de Genève Berne, November 15, 2017
Update on Hepatitis C Francesco Negro Hôpitaux Universitaires de Genève Berne, November 15, 2017 The global prevalence of HCV was 1 0% (95% uncertainty interval 0 8 1 1) in 2015: 71 1 million (62 5 79
More informationUniversal HCV treatment: Strategies for simplification
Universal HCV treatment: Strategies for simplification PARIS HEPATOLOGY CONFERENCE 3 January 217 Tarik Asselah (MD, PhD) Hepatology & Chief INSERM UMR 1149, Hôpital Beaujon, Clichy, France. Disclosures
More informationGlecaprevir-Pibrentasvir in Non-Cirrhotic Genotype 2 ENDURANCE-2
Phase 3 Treatment Naïve or Experienced Glecaprevir-Pibrentasvir in Non-Cirrhotic Genotype 2 ENDURANCE-2 *ENDURANCE-2: Study Features ENDURANCE-2 Trial Design: Randomized, double-blind, placebo-controlled
More informationHCV Treatment Failure: What Next? Dr Ashley Brown, Imperial College Healthcare NHS Trust, London
HCV Treatment Failure: What Next? Dr Ashley Brown, Imperial College Healthcare NHS Trust, London European HIV Hepatitis Co-infection Conference QEII Conference Centre 10 th December 2015 Dr Ashley Brown
More informationClinical Criteria for Hepatitis C (HCV) Therapy
Diagnosis Clinical Criteria for Hepatitis C (HCV) Therapy Must have chronic hepatitis C (HCV infection > 6 months), genotype and sub-genotype specified to determine the length of therapy; Liver biopsy
More informationDisclosures. Advanced HCV management. Overview. Renal failure 1/10/2018. Research Grant support to UCSF from AbbVie Gilead Merck Proteus NIH
Disclosures Advanced HCV management Annie Luetkemeyer, MD Division of HIV, ID and Global Medicine ZSFG, UCSF Research Grant support to UCSF from AbbVie Gilead Merck Proteus NIH Overview Renal failure Acute
More informationHepatitis C Agents
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.41 Subject: Hepatitis C Agents Page: 1 of 19 Last Review Date: December 8, 2017 Hepatitis C Agents
More informationHepatitis C Agents
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.41 Subject: Hepatitis C Agents Page: 1 of 20 Last Review Date: March 16, 2018 Hepatitis C Agents Description
More informationINFECTIOUS DISEASE AGENTS: HEPATITIS C - DIRECT - ACTING ANTIVIRAL
Ohio Department of Medicaid Prior Authorization Form Unified PDL HEPATITIS C TREATMENT Member ID# Patient Name: DOB: Patient Address: Provider DEA: Provider NPI: Provider Name: Phone: Provider Address:
More informationVosevi (sofosbuvir/velpatasvir/voxilaprevir)
Vosevi (sofosbuvir/velpatasvir/voxilaprevir) Policy Number: 5.01.646 Last Review: 10/2017 Origination: 10/2017 Next Review: 11/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide
More informationDrug Class Prior Authorization Criteria Hepatitis C
Drug Class Prior Authorization Criteria Hepatitis C Line of Business: Medicaid P & T Approval Date: November 14, 2018 Effective Date: January 1, 2019 This drug class prior authorization criteria have been
More informationWhat is the Optimized Treatment Duration? To Overtreat versus Undertreat. Nancy Reau, MD Associate Professor of Medicine University of Chicago
What is the Optimized Treatment Duration? To Overtreat versus Undertreat Nancy Reau, MD Associate Professor of Medicine University of Chicago Learning Objectives: 1. Discuss patient populations appropriate
More informationManagement of Chronic HCV 2017 and Beyond
Management of Chronic HCV 2017 and Beyond Blaire E Burman, MD Virginia Mason Gastroenterology & Hepatology Relevant Disclosures No financial disclosures to report Leaning Objectives Burden of HCV Prevalence
More informationHIV/HCV Coinfection: Why It Matters and What To Do About It. Cody A. Chastain, MD 10/26/16
HIV/HCV Coinfection: Why It Matters and What To Do About It Cody A. Chastain, MD 10/26/16 Disclosures I have no relevant financial disclosures. Objectives At the end of this lecture, the learner will be
More informationTreatment of HCV : 100 % cure?
Treatment of HCV : % cure? PHC 8 PARIS January 5th, 8 Tarik Asselah (MD, PhD) Professor of Medicine Hepatology, Chief ISERM UMR 49, Hôpital Beaujon, Clichy, France. PHC 8 - www.aphc.info Disclosures Employee
More informationMonitoring Patients Who Are Starting HCV Treatment, Are On Treatment, Or Have Completed Therapy
Monitoring Patients Who Are Starting HCV Treatment, Are On Treatment, Or Have Completed Therapy WV ECHO August 10, 2017 Selection of patients for HCV treatment Despite current guidance to treat everyone,
More informationHepatitis C in Correctional Facilities: Big Problem, Bigger Opportunity. Cody A. Chastain, MD
Hepatitis C in Correctional Facilities: Big Problem, Bigger Opportunity Cody A. Chastain, MD Disclosures Research supported by Gilead Sciences Inc.: Site investigator for HIV/HCV SWITCH Registry Study
More information5/11/2017. Arthur Y. Kim, MD Associate Professor of Medicine Harvard Medical School Boston, Massachusetts
Hepatitis C Virus Infection Management: Curing Is Caring Arthur Y. Kim, MD Associate Professor of Medicine Harvard Medical School Boston, Massachusetts FORMATTED: 04/07/17 Slide 2 of 53 Financial Relationships
More informationThe Dawn of a New Era: Hepatitis C
The Dawn of a New Era: Hepatitis C Naudia L. Jonassaint Assistant Professor of Medicine and Surgery University Pittsburgh School of Medicine December 1, 2015 Objectives After presentation the learner should
More informationTreating Hepatitis C Virus (HCV) Infection
Slide 1 of 42 Treating Hepatitis C Virus (HCV) Infection Susanna Naggie, MD, MHS Associate Professor of Medicine Duke Clinical Research Institute Durham, North Carolina Slide 3 of 42 Learning Objectives
More informationHCV Treatment of Genotype 1: Now and in the Future
HCV Treatment of Genotype 1: Now and in the Future Bruce R. Bacon, MD, FACG James F. King, MD Endowed Chair in Gastroenterology Professor of Internal Medicine Co-Director of the Abdominal Transplant Program
More informationHepatitis C in 2018: From Evolution to Revolution
Hepatitis C in 218: From Evolution to Revolution Arthur Y. Kim, MD Associate Professor of Medicine Harvard Medical School Director, Viral Hepatitis Clinic Massachusetts General Hospital Boston, Massachusetts
More informationObjectives. Objectives. Introduction. Hepatitis A. Hepatitis B. At the end of the presentation, pharmacy technician participants will be able to:
Objectives A Revolution in Medicine: Advances in the Treatment of Hepatitis C Infection Spencer H. Durham, Pharm.D., BCPS (AQ ID) Assistant Clinical Professor of Pharmacy Practice Auburn University Harrison
More informationTreating Hepatitis C in Patients with Advanced Renal Disease
Treating Hepatitis C in Patients with Advanced Renal Disease Seyed Moayed Alavian M.D. Professor of Medicine, Hepatologist alavian@thc.ir Hemodialysis Patients hemodialysis Preventive Strategies Strict
More informationYour Annual Hepatitis C Update
Your Annual Hepatitis C Update Bernadette Jakeman, Pharm.D. Associate Professor University of New Mexico, College of Pharmacy Nimish Patel, Pharm.D., Ph.D. Associate Professor University of California
More informationCCO Official Conference Coverage: Clinical Impact of New Data From AASLD 2015
CCO Official Conference Coverage: Clinical Impact of New Data From AASLD 2015 CCO Official Conference Coverage of the 2015 Annual Meeting of the American Association for the Study of Liver Diseases, November
More informationMavyret (glecaprevir/pibrentasvir)
(glecaprevir/pibrentasvir) Override(s) Prior Authorization Quantity Limit Medication (glecaprevir/pibrentasvir) Approval Duration Based on Genotype, Treatment Status, or Cirrhosis Status. Quantity Limit
More informationHepatitis C Infection: Updated Information for Front Line Workers in Primary Care Settings MAMTA K. JAIN, MD, MPH 2/14/18
Hepatitis C Infection: Updated Information for Front Line Workers in Primary Care Settings MAMTA K. JAIN, MD, MPH 2/14/18 Overview Hepatitis C Virus Prevalence Effects of Hepatitis C Prevention Diagnosis
More informationGenotype 1 HCV in 2016: Clinical Decision Making in a Time of Plenty
Genotype 1 HCV in 216: Clinical Decision Making in a Time of Plenty Ira M. Jacobson, MD Chair, Department of Medicine Mount Sinai Beth Israel Senior Faculty and Vice-Chair, Department of Medicine Icahn
More informationInitial Treatment of HCV G Hugo E. Vargas, MD Professor of Medicine Medical, Director Office of Clinical Research Mayo Clinic Arizona
Initial Treatment of HCV G1 2016 Hugo E. Vargas, MD Professor of Medicine Medical, Director Office of Clinical Research Mayo Clinic Arizona Disclosure Information Disclosure Information Dr. Vargas receives
More informationAll Hands on Deck: Taking on Hepatitis C in Tennessee
All Hands on Deck: Taking on Hepatitis C in Tennessee Cody A. Chastain, MD Assistant Professor of Medicine Viral Hepatitis Program Division of Infectious Diseases Vanderbilt University Medical Center Cody.a.Chastain@Vanderbilt.edu
More informationHepatitis B and Hepatitis C Virus in non-liver Transplant Recipients. Karim Qumosani MD, FRCPC, ABIM, MdMEd Multi-organ Transplant Unit, London
Hepatitis B and Hepatitis C Virus in non-liver Transplant Recipients Karim Qumosani MD, FRCPC, ABIM, MdMEd Multi-organ Transplant Unit, London Financial Disclosures Research Grants Merck, Gilead, Abbvie,
More informationUpdate on chronic hepatitis C treatment: current trends, new challenges, what next?
Update on chronic hepatitis C treatment: current trends, new challenges, what next? Matti Maimets 12.06.2015 MMaimets15 Disclosure this presentation is sponsored by Gilead Sciences MMaimets15 MMaimets15
More informationNew York State HCV Provider Webinar Series. Treatment of HCV/HIV Co-Infection
New York State HCV Provider Webinar Series Treatment of HCV/HIV Co-Infection Objectives Review the epidemiology of HCV and HIV/HCV co-infection Discuss the burden of HIV/HCV co-infection Discuss the treatment
More informationIFN-free therapy in naïve HCV GT1 patients
IFN-free therapy in naïve HCV GT1 patients Paris Hepatitis Conference Paris, 12th January, 2015 Pr Tarik Asselah MD, PhD; Service d Hépatologie & INSERM U773 University Paris Diderot, Hôpital Beaujon,
More informationHIV-HCV Co-Infection in Shobha Swaminathan, MD Associate Professor of Medicine Rutgers New Jersey Medical School
HIV-HCV Co-Infection in 2018 Shobha Swaminathan, MD Associate Professor of Medicine Rutgers New Jersey Medical School AASLD/IDSA and DHHS Guidance: HIV/HCV Coinfection All pts with HIV should be screened
More informationHEPATITIS C. Mitchell L. Shiffman, MD, FACG Director. Liver Institute of Virginia. Richmond and Newport News, VA
NEW TREATMENTS FOR HEPATITIS C Mitchell L. Shiffman, MD, FACG Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, VA Liver Institute of Virginia Education, Research
More informationState of Maine Department of Health & Human Services MaineCare/MEDEL Prior Authorization Form HEPATITIS C TREATMENT
State of Maine Department of Health & Human Services MaineCare/MEDEL Prior Authorization Form HEPATITIS C TREATMENT HCV Phone: 1-888-445-0497 www.mainecarepdl.org Fax: 1-888-879-6938 Member ID #: Patient
More informationDrug Class Monograph
Drug Class Monograph Class: Chronic Hepatitis C Drugs(s): Daclatasvir (Daklinza), Dasabuvir/ombitasivir/paritaprevir/ritonavir (Viekira Pak), Elbasvir/grazoprevir (Zepatier), Peginterferon alfa-2a (Pegasys),
More informationHepatitis C in Special Populations
Hepatitis C in Special Populations David E. Bernstein, MD, FACG Vice Chairman of Medicine for Clinical Trials Chief, Division of Hepatology and Sandra Atlas Bass Center for Liver Diseases Northwell Health
More informationPharmacy Medical Necessity Guidelines: Hepatitis C Virus
Pharmacy Medical Necessity Guidelines: Hepatitis C Virus Effective: January 1, 2018 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX)
More informationDisclosures. Lisa M. Chirch, MD, FIDSA has disclosed that she has served on advisory boards for Gilead Sciences and Melinta Therapeutics.
HEPATITIS C IN 2017 Lisa M. Chirch, M.D. Associate Professor of Medicine University of Connecticut Health Center A Local Performance Site of the New England AETC Disclosures Lisa M. Chirch, MD, FIDSA has
More informationRATIONALE FOR INCLUSION IN PA PROGRAM
RATIONALE FOR INCLUSION IN PA PROGRAM Background Hepatitis C is a viral disease that causes inflammation of the liver that can lead to diminished liver function or liver failure. Most people infected with
More informationCases: Management of Hepatitis C in Prior Treatment Failure
Cases: Management of Hepatitis C in Prior Treatment Failure David L. Wyles, MD Professor of Medicine University of Colorado Chief, Division of Infectious Disease Denver Health Learning Objectives After
More informationGenotype 1 Treatment Naïve No Cirrhosis Options
Genotype 1 Treatment Naïve No Cirrhosis Options Elbasvir/Grazoprevir (Zepatier ) x 12 weeks 1 Glecaprevir/Pibrentasvir (Mavyret ) x 8 weeks Ledipasvir/Sofosbuvir (Harvoni ) x 8-12 weeks 2 1 If genotype
More information